Wednesday - July 29, 2026
FDA Approves High Dose Regimen of SPINRAZA for Spinal Muscular Atrophy, Reflecting Progress Made Possible Through Decades of MDA Supported Research
March 30, 2026
CHICAGO, Illinois, March 30 -- The Muscular Dystrophy Association issued the following news release:

* * *

FDA Approves High Dose Regimen of SPINRAZA for Spinal Muscular Atrophy, Reflecting Progress Made Possible Through Decades of MDA Supported Research

MDA's research funding for Dr. Adrian Krainer's research led to the groundbreaking discovery of SPINRAZA.

*

NEW YORK - The Muscular Dystrophy Association (MDA) celebrates . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products